Marco Meglio, Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at email@example.com
Mendelian Randomization Study Suggests Narcolepsy Increases Risk of Heart Failure and Coronary Artery Disease
The findings further supported the idea that prevention and assessment of cardiovascular risk in patients with narcolepsy is critical to ongoing care.
BTK Inhibitor Evobrutinib Fails to Meet Primary End Points in Phase 3 EVOLUTION Trials
Results showed that evobrutinib did not produce a more superior reduction in annualized relapse rates than teriflunomide, a previously approved disease-modifying agent.
ALS Candidate PrimeC Meets Primary Safety and Secondary End Points in Phase 2b PARADIGM Study
Although not powered for statistical significance, results showed improvements in ALS Functional Rating Scale and slow vital capacity after treatment with PrimeC.
NeuroVoices: Cathleen Lutz, PhD, on the Potential of Stathmin-2 as an ALS-Specific Biomarker
The vice president of the Rare Disease Translational Center at the Jackson Laboratory provided context on a recently published study suggesting restoration of stathmin-2 as a therapeutic approach for ALS.
Ketogenic Diet Effective and Tolerable to Reduce Seizures in Infants
Although a small-scale study, most infants had a positive response to ketogenic diet, with even greater effects seen in those with Ohtahara syndrome.
FDA Places Clinical Hold on Roche’s BTK Inhibitor Fenebrutinib for Multiple Sclerosis
The clinical hold is in reference to safety concern observed in the phase 3 FENhance studies of patients with relapsing forms of multiple sclerosis.
FDA Clears Vivos CARE Appliance for Severe Obstructive Sleep Apnea
With the approval, the appliances represent an alternative treatment to CPAP or surgical neurostimulation implants for patients with severe OSA.
Concomitant Clobazam, Valproate Improves Ganaxolone’s Impact on Motor Seizure Frequency in CDKL5 Deficiency Disorder
Clobazam and valproate, when used concomitantly, produced a greater treatment effect with ganaxolone than other antseizure medications levetiracetam and vigabatrin.
Vigabatrin Demonstrates Significant Seizure Suppression in Super Refractory Status Epilepticus
The retrospective cohort study, led by R. Eugene Ramsay, MD, highlighted the impacts of vigabatrin in patients with super refractory status epilepticus.
Positive Impacts on Non-Seizure Symptoms, Caregiver Experience Observed With Soticlestat
Using a caregiver questionnaire, noted improvements in verbal, non-verbal communication, and engagement were observed on soticlestat treatment.
Efficacy and Safety of Antiseizure Medication Brivaracetam Maintained in Asian Patients
Over a 12-week trial period, Asian patients treated with brivaracetam demonstrated efficacy and safety outcomes that were similar to other populations previously observed.
Fetal Outcomes Largely Unaffected by Antiseizure Medication Lacosamide
In an analysis of lacosamide in pregnant women, a low number of preterm birth deliveries were reported, with no new safety concerns identified.
Long-Term CBD Treatment in Tuberous Sclerosis Complex Effective Regardless of Age
Both pediatric and adult patients with tuberous sclerosis complex demonstrated significant reductions in TSC-associated seizures with no new safety concerns identified.
Episode 103: Advancing Epilepsy Care and Seizure Localization in Pediatrics
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with William Gallentine, DO. [LISTEN TIME: 17 minutes]
FDA Extends Review Time for Italfarmaco’s Duchenne Agent Givinostat
Givinostat, a HDAC inhibitor, was supported by data from the phase 3 EPIDYS study, a randomized, double-blind, placebo-controlled, multicenter trial.
PREDICT-PD Algorithm Shows Ability to Identify Early Motor Dysfunction, Parkinsonism
PREDICT-PD, a low intensity and cost-efficient assessment, was able to estimate the occurrence of motor disturbances in the future, in particular sub-threshold parkinsonism and bradykinesia.
Acadia Initiates Phase 2 Study of Investigational Agent ACP-204 in Alzheimer Psychosis
ACP-204, an inverse agonist at the 5-HT2A receptor, builds upon the learnings of pimavanserin (Nuplazid) in the treatment of neuropsychiatric symptoms.
Building on Momentum: Overviewing Ongoing Efforts from the Alzheimer’s Association
Heather Synder, PhD, vice president of medical and scientific relations at the Alzheimer’s Association, gave thoughts on the recently concluded CTAD conference and how the organization plans to carry the positive momentum in the field.
NeuroVoices: Emad Estemalik, MD, on Pioneering a New Age of Migraine Care
The director of the headache section at Cleveland Clinic’s Neurological Institute provided thoughts on how recent advances have propelled migraine care, treatment possibilities behind prevention, and emerging research targets.
Considerations Amid the Ever-Changing Field of Alzheimer Disease
Alvaro Pascual-Leone, MD, PhD, director of the Berenson-Allen Center for Noninvasive Brain Stimulation at Beth Israel Deaconess Medical Center, provided commentary on the ways Alzheimer disease treatment has changed and how clinicians will need to adapt in the coming years.
Patient Headache Questionnaire Leads to Greater Diagnosis Rates, Less Non-Specific Diagnoses in Children
The odds of making a specific diagnosis nearly doubled when the patient headache questionnaire was employed, resulting in more accurate identification and subsequent treatment of migraine cases.
High Rates of Depression, Anxiety, and Sleep Disturbances Found in NMOSD
Across 31 studies of patients with NMOSD, more than half of the patients included reported having sleep disturbances associated with their condition.
Biosimilars Enter the Multiple Sclerosis Treatment Paradigm
A panel of experts provide commentary on a range of topics regarding the
integration of biosimilars in the management of multiple sclerosis, including the
supporting data behind these agents and how the clinical community can adapt.
Fetal Exposure to Antiseizure Medications During Third Trimester May Increase Risk for Worse Functioning in Children
Significant associations between higher third-trimester ASM concentrations with poorer adaptive and behavior outcomes were seen on several assessments, including the Adaptive Behavior Assessment System, Third Edition.
Adherence to Multiple Sclerosis Disease-Modifying Therapy Lowers Risk of Relapse, Severe Relapse
The study added to the evidence base for recommending adherence to treatment with disease-modifying therapies in clinical practice, a key element for reducing moderate or severe relapse rate.
Levodopa-Entacapone-Carbidopa Intestinal Gel Shows Minimal Benefits Over Traditional Parkinson Therapies
Apart from the small pump system, which was preferred by the patients, the study found no clear advantage of levodopa-entacapone-carbidopa to levodopa-carbidopa intestinal gel.
NeuroVoices: Paula Barreras, MD, on the 2023 Spanish RNDS Hosted by SRNA
The physician neurologist and neuroimmunologist at Cedars Sinai Medical Center discussed RNDS 2023, an educational event for Spanish-speaking patients with rare neuroimmune disorders.
FDA Clears AI-Powered Brain MRI Software Pixyl.Neuro
Pixyl.Neuro, a CE-marked medical device, is designed to be integrated into the radiology workflow, providing clinicians with diagnostic support of neuroinflammatory and neurodegenerative disorders.
Sodium Oxybate Shows Potential as Effective Therapy for Alcohol-Responsive Essential Tremor of Voice
In a phase 2 study, sodium oxybate showed a significant, albeit short-lived, reduction in voice symptoms for patients with alcohol-responsive essential tremor of voice.
First Patient Dosed in Phase 1 Trial of Gene Therapy AB-1005 in Multiple System Atrophy-Parkinsonian Type
The double-blind, placebo-controlled study is expected to include 9 patients aged 35-75 years old with MSA-parkinsonian type who will be randomized 2:1 to either investigational AB-1005 or sham surgery.
2 Clarke Drive Cranbury, NJ 08512